Nykode Therapeutics Announces Expansion of Clinical Collaboration with Roche to Evaluate VB10.16 in Combination with anti-PD-L1 in the next trial in Advanced Cervical Cancer
June 01, 2023 00:45 ET
|
Nykode Therapeutics
OSLO, Norway, June 01, 2023 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies,...
Nykode Therapeutics to Present at Jefferies Healthcare Conference
May 30, 2023 12:00 ET
|
Nykode Therapeutics
OSLO, Norway, May 30, 2023 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies,...
Nykode Therapeutics announces positive final results from its Phase 2 trial of VB10.16 in combination with PD-L1 inhibitor atezolizumab in advanced cervical cancer
April 18, 2023 11:00 ET
|
Nykode Therapeutics
The results showed median overall survival greater than 25 months (not reached) and 6.3 months median progression free survival in PD-L1+ patientsVB10.16 was safe and well tolerated in combination...
Nykode Therapeutics to announce financial results for the fourth quarter 2022 and host webcast presentation on February 28, 2023
February 22, 2023 07:00 ET
|
Nykode Therapeutics
OSLO, Norway, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies,...
Nykode Therapeutics Announces Collaboration with The GOG Foundation, Inc. to Conduct the VB-C-04 Trial in Advanced Cervical Cancer
February 10, 2023 00:45 ET
|
Nykode Therapeutics
Potentially registrational VB-C-04 trial in the U.S. expected to initiate 4Q 2023The GOG Foundation, Inc. (GOG) is a U.S. based not-for-profit organization with the purpose of promoting excellence in...
Nykode Therapeutics to Present at SVB Securities Global Biopharma Conference
February 07, 2023 07:00 ET
|
Nykode Therapeutics
OSLO, Norway, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies,...
Nykode Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
December 23, 2022 05:00 ET
|
Nykode Therapeutics
OSLO, Norway, Dec. 23, 2022 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies,...
Nykode announces expanded clinical development plan for its lead cancer vaccine VB10.16 in HPV16-positive cancers
December 20, 2022 00:45 ET
|
Nykode Therapeutics
A trial in advanced cervical cancer will be initiated in 4Q2023 with potential registrational intentDose-finding Phase 1/2a trial in 1st line patients with advanced head and neck squamous cell...
Nykode Therapeutics and Richter-Helm BioLogics Announce Strategic Manufacturing Partnership
December 19, 2022 00:45 ET
|
Nykode Therapeutics
OSLO, Norway, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies,...
Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 in Combination With KEYTRUDA® (pembrolizumab) in Patients with HPV16-Positive Head and Neck Cancer
December 06, 2022 10:45 ET
|
Nykode Therapeutics
OSLO, Norway, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies,...